Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03868358
Other study ID # ahmu-sjnk-scz
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 21, 2017
Est. completion date March 30, 2021

Study information

Verified date April 2021
Source Anhui Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate the treatment effect of intermittent theta-burst transcranial magnetic stimulation on symptomatic relief of schizophrenia patients, and the underlying neural mechanism by functional MRI and the resting electroencephalogram


Description:

All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after intermittent theta-burst transcranial magnetic stimulation (iTBS) treatment. Patients were randomly allocated to iTBS group and the sham group by coin toss. There are about 30 patients in each group.The decision to enroll a patient was always made prior to randomization. Patients were studied using a double-blind design. Study participants, clinical raters, and all personnel responsible for the clinical care of the patient remained masked to allocated condition and allocation parameters. Only iTBS administrators had access to the randomization list; they had minimal contact with the patients, and no role in assessing the Positive and Negative Syndrome Scale (PANSS). Each patient would be treated for continuous 14 days by iTBS.Before the iTBS treatment, PANSS and Clinical Global Impression-severity of illness (CGI-SI) at baseline were obtained by a trained investigator to assess baseline severity of their symptoms. Scale for the Assessment of Negative Symptoms (SANS) and Scale for Assessment of Positive Symptoms (SAPS) were respectively supplemented to evaluate the severity of symptoms in different dimensions,.The patients had receiving a battery measure of neuropsychological tests (standardized tests to investigate their cognitive problems, anxiety and depressive symptoms in daily life), magnetic resonance imaging scan in multimodalities, electroencephalography (EEG), event-related potentials during stop signal test and Iowa-gambling test record. Other behavioral tests including intertemporal decision,spatial n-back test record. After the last treatment, the Positive and Negative Syndrome Scale were obtained, as well as the Global Index of Safety to assess adverse events of the treatment. Patients were instructed to focus their answers on the past 14 days. The patients had also receiving a battery measure of neuropsychological tests, magnetic resonance imaging scan in multimodalities, and EEG record.Clinical Global Impression-global improvement (CGI-GI), Clinical Global Impression-efficacy index (CGI-EI) were evaluated at the end of treatment. 40-60 days after the last treatment, participants were interviewed to obtain the Positive and Negative Syndrome Scale,SAPS,SANS and HAMA,HAMD. They were instructed to focus their answers on the past week. Additionally, they were also asked to assess the battery of neuropsychological tests, and have magnetic resonance imaging scan in multimodalities, and EEG record. Afterwards, they were unblinded by the study coordinator.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 30, 2021
Est. primary completion date July 9, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 52 Years
Eligibility Inclusion Criteria: - Patients met diagnostic criteria for schizophrenia or schizoaffective disorder using the Structural Clinical Interview for Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-IV (SCID, Version 2.0). - Patients remain their psychotropic medication at steady dosages for at least 4 weeks prior to study entry and for the duration of the trial. - Verbal intelligence quotient > 85 as measured by using a Chinese version of the National Adult Reading Test. Exclusion Criteria: - History of significant head trauma or neurological disorders - Alcohol or drug abuse Focal brain lesions on T1- or T2-weighted fluid-attenuated inversion-recovery magnetic resonance images - a prior history of a seizure not induced by drug withdrawal,first degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease, such as thyroid disease, significant unstable medical condition, recent aggression or other forms of behavioral dyscontrol - left-handedness, pregnancy - estimated intelligence quotient<80 - current alcohol or drug abuse - inability to provide informed consent. - Hamilton Anxiety Rating Scale or the Hamilton Depression Rating Scale score > 14

Study Design


Related Conditions & MeSH terms

  • Functional Magnetic Resonance Imaging
  • Schizophrenia
  • Transcranial Magnetic Stimulation

Intervention

Device:
transcranial magnetic stimulation
The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks. Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks

Locations

Country Name City State
China Anhui Medical University Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
WANG KAI

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive And Negative Syndrome Scale(PANSS) The improvment in PANSS scores will constitute the major research outcome measure used to assess response to rTMS,reflecting the symptom improvment in patients Baseline and 2 weeks post-treatment,and follow-up
Secondary Scale for the Assessment of Positive Symptoms (SAPS) The improvment in SAPS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' positive symptoms Baseline and 2 weeks post-treatment and follow-up
Secondary Scale for the Assessment of Negative Symptoms (SANS) The improvment in SANS scores will constitute the major research outcome, and specifically reflect the degree of improvement in patients' negative symptoms Baseline and 2 weeks post-treatment and follow-up
Secondary Functional connectivity change of transcranial magnetic stimulation(iTBS and sham) Functional MRI measures: the functional connectivity between stimulated target and the whole brain areas Baseline and 2 weeks post-treatment
Secondary EEG change of transcranial magnetic stimulation(iTBS and sham) EEG measures: brain areas wave change of stimulation(iTBS and sham) Baseline and 2 weeks post-treatment
Secondary Intertemporal decision test Intertemporal decision test is associated with the function of left dorsolateral prefrontal cortex Baseline and 2 weeks post-treatment
Secondary Spatial n-back test Spatial n-back test will reflect the prefrontal function Baseline and 2 weeks post-treatment
Secondary Multidimensional Empathy Test Multidimensional empathy Test is associated with the function of left dorsolateral prefrontal cortex Baseline and 2 weeks post-treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A